Plasma Fractionation

REPORT HIGHLIGHTS

Global Plasma Fractionation Market to Reach US$70.8 Billion by 2032

The global market for Plasma Fractionation estimated at US$40.8 Billion in the year 2025, is expected to reach US$70.8 Billion by 2032, growing at a CAGR of 8.2% over the analysis period 2025-2032. Albumin Type, one of the segments analyzed in the report, is expected to record a 9.6% CAGR and reach US$27.6 Billion by the end of the analysis period. Growth in the Immunoglobulins Type segment is estimated at 5.9% CAGR over the analysis period.

The U.S. Market is Estimated at US$12.1 Billion While China is Forecast to Grow at 7.9% CAGR

The Plasma Fractionation market in the U.S. is estimated at US$12.1 Billion in the year 2025. China, the world`s second largest economy, is forecast to reach a projected market size of US$12.5 Billion by the year 2032 trailing a CAGR of 7.9% over the analysis period 2025-2032. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 7.8% and 6.8% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 6.4% CAGR.

Global Plasma Fractionation Market - Key Trends and Drivers Summarized

Harnessing Vital Proteins: The Process of Plasma Fractionation

Plasma fractionation is a sophisticated biotechnological process used to separate and purify different components from blood plasma. Plasma, the liquid portion of blood, contains a variety of proteins and other substances essential for medical treatments. The fractionation process begins with the collection of plasma through donation. Once collected, the plasma undergoes a series of steps, including centrifugation, filtration, and chromatography, to isolate specific proteins. These proteins, such as albumin, immunoglobulins, and clotting factors, are then purified and concentrated for therapeutic use. Each step in the fractionation process is carefully controlled to ensure the purity, efficacy, and safety of the final products, which are used to treat a range of medical conditions, from immune deficiencies and bleeding disorders to shock and trauma.

How Are Plasma-Derived Products Utilized in Medicine?

Plasma-derived products play a critical role in modern medicine, offering life-saving treatments for various conditions. Albumin, one of the major proteins isolated through plasma fractionation, is used to treat patients with severe burns, liver diseases, and hypoalbuminemia by helping maintain blood volume and pressure. Immunoglobulins, or antibodies, are essential for treating immune deficiencies and autoimmune diseases. They provide passive immunity to patients, enhancing their ability to fight infections. Clotting factors, such as Factor VIII and Factor IX, are crucial for patients with hemophilia, a genetic disorder that impairs blood clotting. These products help prevent and control bleeding episodes, significantly improving the quality of life for hemophilia patients. The diverse applications of plasma-derived products underscore their importance in addressing a wide range of medical needs and enhancing patient care.

What Are the Current Trends in Plasma Fractionation Technology?

The plasma fractionation industry is continuously evolving, driven by advancements in technology and a growing understanding of plasma proteins. One significant trend is the improvement in purification techniques, such as advanced chromatography and filtration methods, which enhance the yield and purity of plasma-derived products. Another trend is the development of recombinant DNA technology, which allows for the production of certain plasma proteins in a laboratory setting, reducing dependence on plasma donations and increasing the availability of these critical therapies. The integration of automation and digital technologies is also transforming plasma fractionation, enabling more efficient and scalable production processes. Additionally, there is a growing focus on expanding the range of therapeutic applications for plasma-derived products, including the treatment of emerging diseases and conditions. These technological advancements and innovative approaches are shaping the future of plasma fractionation, making therapies more effective and accessible.

What Factors Are Driving the Growth in the Plasma Fractionation Market?

The growth in the plasma fractionation market is driven by several factors, each reflecting the increasing demand for plasma-derived therapies. The rising prevalence of chronic diseases and genetic disorders, such as hemophilia and primary immune deficiencies, is a significant driver, as these conditions require regular and long-term treatment with plasma-derived products. Technological advancements in fractionation processes and the development of recombinant therapies are enhancing the efficiency and scalability of production, meeting the growing demand. The expansion of healthcare infrastructure in developing regions is increasing access to plasma-derived therapies, contributing to market growth. Additionally, the aging global population is driving demand for treatments for age-related conditions, such as liver disease and immunodeficiencies. The emphasis on improving patient outcomes and the ongoing research into new therapeutic applications for plasma proteins further support market expansion. These factors collectively ensure robust growth in the plasma fractionation market, highlighting its critical role in modern healthcare and therapeutic development.

SCOPE OF STUDY:

The report analyzes the Plasma Fractionation market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:
Type (Albumin Type, Immunoglobulins Type, Coagulation Factors Type, Protease Inhibitors Type, Other Types); Method (Centrifugation Method, Depth Filtration Method, Chromatography Method, Other Methods); Application (Neurology Application, Hematology Application, Oncology Application, Immunology Application, Pulmonology Application, Other Applications); End-Use (Hospitals & Clinics End-Use, Clinical Research End-Use, Other End-Uses)

Geographic Regions/Countries:
World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.

SELECT PLAYERS -

• Bio Products Laboratory Ltd.
• Biotest AG
• China Biologic Products, Inc.
• CSL Limited
• Green Cross Corporation
• Grifols SA
• Japan Blood Products Organization
• Kedrion SpA
• LFB SA
• Octapharma AG
• Sanquin
• Shanghai RAAS Blood Products Co., Ltd.
• Shire PLC

Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher. Show more